Unigene Laboratories

This article needs additional citations for verification. Please help by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources:  –  ·  ·  · scholar · JSTOR (March 2012) (Learn how and when to remove this template message)

This article does not cite any sources. Please help by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources:  –  ·  ·  · scholar · JSTOR (July 2020) (Learn how and when to remove this template message)

Unigene Laboratories

Type	Public
Traded as	OTC Pink No Information: UGNEQ
Industry	Biotechnology
Headquarters	Boonton  , United States
Key people	Ashleigh Palmer, President and CEO Gregory T. Mayes, Esq., Vice President, Corporate Development and General Counsel Nozer Mehta, Ph.D., Vice President, Biological Research and Development Paul Shields, Ph.D., Vice President, Technology Transfer and Contract Manufacturing Services William Steinhauer, CPA Vice President, Finance Roxanne Tavakkol, Vice President, Global Regulatory Affairs Jenene Thomas, Vice President, Investor Relations and Business Administration
Website	www.unigene.com

Unigene Laboratories (OTC:UGNE) was a biopharmaceutical company, engaged in the research and development of peptides for medical purposes. The company was founded in 1980 and is located in New Jersey.

The company's primary focus is on the development of calcitonin and related peptides for the treatment of osteoporosis. The company has licensed worldwide rights to its oral parathyroid hormone ("PTH") to GlaxoSmithKline.

Unigene filed for Chapter 7 bankruptcy on July 2, 2013 in the United States Bankruptcy Court of the District of New Jersey. The Chapter 7 case is being administered under case No. 13-24696.

See also[]

• UgMicroSatdb

References[]

External links[]

• Corporate website